S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Passage Bio Stock Forecast, Price & News

-0.59 (-7.59%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.36 million shs
Average Volume
385,976 shs
Market Capitalization
$388.49 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PASG News and Ratings via Email

Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter.

Passage Bio logo

About Passage Bio

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (Ã-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$6.69 per share


Net Income
$-112.23 million
Pretax Margin




Free Float
Market Cap
$388.49 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.48 out of 5 stars

Medical Sector

141st out of 1,390 stocks

Biological Products, Except Diagnostic Industry

19th out of 202 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Passage Bio (NASDAQ:PASG) Frequently Asked Questions

Is Passage Bio a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Passage Bio stock.
View analyst ratings for Passage Bio
or view top-rated stocks.

How has Passage Bio's stock price been impacted by COVID-19?

Passage Bio's stock was trading at $18.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PASG shares have decreased by 61.9% and is now trading at $7.18.
View which stocks have been most impacted by COVID-19

When is Passage Bio's next earnings date?

Passage Bio is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Passage Bio

How were Passage Bio's earnings last quarter?

Passage Bio, Inc. (NASDAQ:PASG) posted its earnings results on Thursday, November, 4th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.07. During the same quarter last year, the company earned ($0.63) EPS.
View Passage Bio's earnings history

What price target have analysts set for PASG?

8 equities research analysts have issued 1-year price targets for Passage Bio's stock. Their forecasts range from $2.21 to $45.00. On average, they expect Passage Bio's share price to reach $27.03 in the next twelve months. This suggests a possible upside of 276.4% from the stock's current price.
View analysts' price targets for Passage Bio
or view top-rated stocks among Wall Street analysts.

Who are Passage Bio's key executives?

Passage Bio's management team includes the following people:
  • Dr. Bruce A. Goldsmith M.B.A., Ph.D., CEO, Pres & Director (Age 55, Pay $756.92k)
  • Ms. Jill M. Quigley Esq., J.D., Chief Operating Officer (Age 45, Pay $997.67k)
  • Dr. James M. Wilson M.D., Ph.D., Co-Founder & Chief Scientific Advisor (Age 66)
  • Mr. Alexandros Fotopoulos MSc, MBA, Chief Technical Officer (Age 52)
  • Mr. Stuart M. Henderson, VP Investor Relations & Strategic Fin.
  • Mr. Edgar B. Cale Esq., J.D., Gen. Counsel & Company Sec. (Age 57)
  • Robin DeRogatis, VP HR
  • Dr. Eliseo Oreste Salinas, Chief R&D Officer and Interim Chief Medical Officer (Age 65)

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX).

When did Passage Bio IPO?

(PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager.

What is Passage Bio's stock symbol?

Passage Bio trades on the NASDAQ under the ticker symbol "PASG."

Who are Passage Bio's major shareholders?

Passage Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.76%), Morgan Stanley (2.11%), Geode Capital Management LLC (0.87%), Wellington Management Group LLP (0.78%), Millennium Management LLC (0.64%) and Bank of New York Mellon Corp (0.58%). Company insiders that own Passage Bio stock include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Gary Romano, Jill M Quigley, Life Sciences Ix LP Frazier, Richard Steven Morris and Thomas Woiwode.
View institutional ownership trends for Passage Bio

Which institutional investors are selling Passage Bio stock?

PASG stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Marshall Wace LLP, Citigroup Inc., Geode Capital Management LLC, Cubist Systematic Strategies LLC, California State Teachers Retirement System, Squarepoint Ops LLC, and New York State Common Retirement Fund. Company insiders that have sold Passage Bio company stock in the last year include Gary Romano, and Jill M Quigley.
View insider buying and selling activity for Passage Bio
or view top insider-selling stocks.

Which institutional investors are buying Passage Bio stock?

PASG stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Renaissance Technologies LLC, Wellington Management Group LLP, SG Americas Securities LLC, Trexquant Investment LP, and Goldman Sachs Group Inc.. Company insiders that have bought Passage Bio stock in the last two years include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Jill M Quigley, Life Sciences Ix LP Frazier, Richard Steven Morris, and Thomas Woiwode.
View insider buying and selling activity for Passage Bio
or or view top insider-buying stocks.

How do I buy shares of Passage Bio?

Shares of PASG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Passage Bio's stock price today?

One share of PASG stock can currently be purchased for approximately $7.18.

How much money does Passage Bio make?

Passage Bio has a market capitalization of $388.49 million. The company earns $-112.23 million in net income (profit) each year or ($3.38) on an earnings per share basis.

How many employees does Passage Bio have?

Passage Bio employs 74 workers across the globe.

What is Passage Bio's official website?

The official website for Passage Bio is www.passagebio.com.

Where are Passage Bio's headquarters?

How can I contact Passage Bio?

Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The company can be reached via phone at 267-866-0311 or via email at [email protected].

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.